GW Pharmaceuticals PLC- (NASDAQ:GWPH) saw some unusual options trading activity on Tuesday. Investors purchased 2,364 put options on the stock. This is an increase of 1,466% compared to the typical volume of 151 put options.
Shares of GW Pharmaceuticals PLC- (NASDAQ GWPH) opened at $126.90 on Friday. The company has a current ratio of 11.44, a quick ratio of 7.47 and a debt-to-equity ratio of 0.01. GW Pharmaceuticals PLC- has a 12-month low of $92.65 and a 12-month high of $143.37. The firm has a market cap of $3,220.00, a price-to-earnings ratio of -14.31 and a beta of 2.50.
GW Pharmaceuticals PLC- (NASDAQ:GWPH) last announced its quarterly earnings results on Monday, February 5th. The biopharmaceutical company reported ($2.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.03) by ($0.40). GW Pharmaceuticals PLC- had a negative return on equity of 46.94% and a negative net margin of 1,357.98%. The business had revenue of $7.73 million for the quarter, compared to analysts’ expectations of $2.18 million. analysts anticipate that GW Pharmaceuticals PLC- will post -7.76 earnings per share for the current year.
Several analysts have recently issued reports on the stock. Bank of America lowered their price objective on shares of GW Pharmaceuticals PLC- from $154.00 to $149.00 and set a “buy” rating for the company in a research note on Tuesday. Leerink Swann boosted their price objective on shares of GW Pharmaceuticals PLC- from $153.00 to $157.00 and gave the company an “outperform” rating in a research note on Tuesday. Cantor Fitzgerald reaffirmed a “buy” rating and set a $192.00 price target (down from $208.00) on shares of GW Pharmaceuticals PLC- in a research report on Monday. Zacks Investment Research raised shares of GW Pharmaceuticals PLC- from a “sell” rating to a “hold” rating in a research report on Tuesday, January 30th. Finally, BidaskClub cut shares of GW Pharmaceuticals PLC- from a “buy” rating to a “hold” rating in a research report on Tuesday, January 9th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $146.38.
About GW Pharmaceuticals PLC-
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.